ABOUT ENZYCHEM LIFESCIENCES
Enzychem Lifesciences (KOSDAQ:183490) is developing novel small molecule therapeutics to target fundamental pathways in inflammation, patients with significant unmet needs in oncology, inflammatory, and severe respiratory diseases. Based on more than two decades of research, we developed our leading candidate EC-18(Mosedipimod), an oral small molecule derived from Sika deer antler, which has shown to be active across a number of different indications.
LIPID MEDICINE PLATFORM TECHNOLOGY
EC-18 targets anti-inflammatory
pathway
Broad therapeutic platform
Developing first-in-class small molecules to target
fundamental inflammation pathways
EC-18 PIPELINE
DEVELOPMENT STAGE
CRIOM: Chemoradiation-induced Oral Mucositis
CIN: Chemotherapy-induced Neutropenia
ARS: Acute Radiation Syndrome
COVID-19: Coronavirus Disease-19
ICI: Immune Checkpoint Inhibitors (PD-1, PD-L1)
NASH: Non-alcoholic Steatohepatitis
Press Releases
WRITTEN BY
admin
엔지켐생명과학, API·록피드 기반에 혁신신약·PDRN 사업 확장
기사 전문은 링크를 통해 확인하실 수 있습니다. 출처&링크: https://www.pharmnews.com/news/articleView.html?idxno=307100
WRITTEN BY
admin
엔지켐생명과학 ‘록피드’, 세계한상대회서 면역 건기식 글로벌 시장 정조준
기사 전문은 링크를 통해 확인하실 수 있습니다. 출처&링크: https://www.pharmnews.com/news/articleView.html?idxno=306611
WRITTEN BY
admin
엔지켐생명과학, 주총 52% 찬성…“거래 재개에 총력”
기사 전문은 링크를 통해 확인하실 수 있습니다. 출처&링크: https://www.the-today.com/news/articleView.html?idxno=88570